• Initiative aims to understand Variability in Cell Culture Media
    Expansive facilities at NIBRT

News & Views

Initiative aims to understand Variability in Cell Culture Media

Mar 25 2022

NIBRT, Kerry Group and ValitaCell are collaborating on a strategic initiative to validate the role of protein hydrolysates in cell culture media during the commercial manufacture of biotherapeutics. The manufacturing process at a commercial scale involves the growth of mammalian cells in a multi-component liquid media and Kerry has commercialised protein hydrolysates from various sources as bioactive components to be used in mammalian cell cultures for this purpose.   

The raw material for the production of these hydrolysates includes a variety of plant and microbial sources such as soy, yeast, cotton and wheat. However, the variability in the performance of these hydrolysates is not well understood; the hydrolysates are chemically undefined and contain complex composition dependent on the raw material used. The challenge for the biopharmaceutical industry is that cell culture media is one of the most difficult components to control. This initiative, which is supported by Enterprise Ireland under the Innovation Partnership programme, will use ViltaCell’s ChemStress® platform to characterise the behaviour of cells using a panel of specific, small molecule chemical stressors.  The assay is carried out on a multiwell plate and enables the rapid screening of the robustness of cells within the specific environment of each well.

The programme of work is to be conducted at NIBRT facilities under the guidance of Prof. Michael Butler.

“ValitaCell have invested significant resources in our ChemStress® platform to provide scientists with a Biological prism of their manufacturing environment, in microscale. Working with Kerry Group and NIBRT on this specific validation problem is a great opportunity to demonstrate the power of our technology in the Cell Culture media component sector,” said Dr. Jerry Clifford, CEO at ValitaCell.

“We are delighted at NIBRT to receive funding from Enterprise Ireland in collaboration with the Kerry Group and ValitaCell to enable a study of the bioactive properties of plant and microbial sourced hydrolysates using the ChemStress® platform technology.  This research will enable an understanding of the functional role of hydrolysates in cell culture media that will promote the efficient production of biotherapeutics from bioprocesses,” commented  Prof Michael Butler, Principal Investigator in the Cell Technology Group at NIBRT.

More information online

Digital Edition

Lab Asia 29.6 Dec

December 2022

In This Edition Chromatography - Optimising Viral Vector Purification Strategies with Multimodal Chromatography - Key UHPLC Characteristics Required for High throughput LC-MS - New Low Volu...

View all digital editions


Nano Tech 2023

Feb 01 2023 Tokyo, Japan

Medlab Middle East

Feb 06 2023 Dubai, UAE


Feb 14 2023 Cologne, Germany

SLAS 2023

Feb 25 2023 San Diego, CA, USA

View all events